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Circulating Tumor Cells (CTCs) are cancer cells that split away from the primary tumor and
appear in the circulatory system as singular units or clusters, which was ﬁrst reported by
Dr. Thomas Ashworth in 1869. CTCs migrate and implantation occurs at a new site, in a
process commonly known as tumor metastasis. In the case of breast cancer, the tumor
cells often migrate into locations such as the lungs, brain, and bones, even during the early
stages, and this is a notable characteristic of breast cancer. Survival rates have increased
signiﬁcantly over the past few decades because of progress made in radiology and tissue
biopsy, making early detection and diagnosis of breast cancer possible. However, liquid
biopsy, particularly that involving the collection of CTCs, is a non-invasive method to
detect tumor cells in the circulatory system, which can be easily isolated from human
plasma, serum, and other body ﬂuids. Compared to traditional tissue biopsies, ﬂuid
sample collection has the advantages of being readily available and more acceptable to
the patient. It can also detect tumor cells in blood earlier and in smaller numbers, possibly
allowing for diagnosis prior to any tumor detection using imaging methods. Because of the
scarcity of CTCs circulating in blood vessels (only a few CTCs among billions of
erythrocytes and leukocytes), thorough but accurate detection methods are particularly
important for further clinical applications.
Keywords: CTCs, breast cancer, clinical application, liquid biopsy, detection methods

INTRODUCTION
Breast cancer has overtaken lung cancer in 2020 to become the most common type of cancer in the
world. The metastatic nature of breast cancer is also of great concern, as metastasis accounts for 90%
of malignancy deaths, because of distal progressions of primary tumors (1). One hypothesis is that
tumor metastasis is triggered via CTCs (circulating tumor cells) that are found in patients’ blood (2).
In a successful dispersal process, cancer cells of breast tumors in primary site inﬁltrate surrounding
tissues, enter blood and lymphatic vessels, followed by translocation to distant sites. The ability to
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characterizes) CTC from other regular cells. Then, CTCs are
identiﬁed and isolated from other normal blood cells (8).

escape from blood vessels and adapt to novel microenvironments
in the body allow cancer cells to successfully implant, colonize
and proliferate in a new site.
Compared to primary cancer cells, circulating tumor cells
show a more aggressive ability to mutate, accumulating genetic
changes similar to or larger than those of the original tumor
through somatic cell mutations and acquisition of additional
characteristics within circulation (3). As the dissemination of
tumors appears to be mostly via the blood, circulating tumor
cells that have penetrated the blood vessels to inﬁltrate potential
metastatic sites are of obvious interest (4); for example, many
studies have concluded that the blood-borne dissemination is
contributed by EMT (epithelial-mesenchymal transition) in
patients with breast cancer (5). Recently, many investigations
into liquid biopsy have been conducted; a considerable number
showed the potential of CTC detection as an effective method for
the evaluation of chemotherapy efﬁcacy, early diagnoses and
malignancy recurrence, and choice of drug sensitivity (6). Liquid
biopsies of CTCs have the following advantages over other tumor
markers in the blood: (1) easy to collect, (2) persistent
assessment, (3) analysis of the overall tumors burden rather
than a limited part of tumors. Given the many beneﬁts of CTCs
have in relation to the early diagnosis and treatment of breast
tumors, early stage detection of CTCs in blood appears to be the
most critical. However, because of the extremely low
concentration of CTCs in human blood, detection has always
been a technical challenge. This has led to more research and
development in relation to detection methods. Recently, the
detection and clinical application of CTCs have been gradually
incorporated into the ﬁeld of nanotechnology and genetics. The
detection methods of CTCs are changing dramatically, and the
clinical applications are becoming increasingly extensive (7). As
a result of the increased attention on this critical subject, multiple
detection methods have been developed, and these methods can
be used to detect circulating tumor cells in vivo as well as in vitro.
This article sets out the current state of recent developments
relating to detection methods, commercial systems, and clinical
applications of CTCs, as well as the limitations and prospects of
each method for reference during clinical processes and as
guidance for researchers and clinicians.

In Vitro Detection Methods
CTCs counts have long been seen as a preferred tool in clinical
diagnosis. Recently, accurate detection of CTCs may soon be
achieved due to many advanced techniques being developed.
Enrichment as well as detection procedures are basics for these
novel techniques. The gathering and detection methods of CTCs
are based on biological or physical features. The latter depends
on size, electrical properties, and other physical characteristics of
tumor cells, while the former depends on antigen-antibody
combinations and the differences of DNA and RNA which
distinguish CTCs from normal cells.

Detection Methods Relying on Physical Properties
CTCs can be identiﬁed from normal cells in blood, such as
leukocytes, through physical isolation, without any biomarker
labeling. The isolation tactics focus on several distinctions in
physical characteristics between cells in blood and CTCs, as set
out in Table 1.
1. ISET (Isolation by Size of Epithelial Tumor cells): Because of
their larger size compared to leukocytes in blood, CTCs can
be easily isolated by diameter. An identical hypothesis, the
nucleoporeassay, is also based on size differences (9, 10).
Overall, ISET equipment allows the isolation of CTM
(circulating tumor microemboli) and CTCs from all kinds
of malignancies as intact cells, without any previous selection
based on immune system. However, proof of the existence of
CTCs smaller than 8 mm has not yet been explored, leaving
questions about the sensitivities of the method.
2. ScreenCell system: Through utilizing a microporous
membrane ﬁlter, ScreenCell systems separate CTCs by cell
size screen, making later characterization and sorting
possible. Filtration membranes, based on microﬁltration
technology, enable nucleated cells to pass while holding up
CTCs. The potential to achieve high throughput persistent
processing of large volumes of blood has been demonstrated.
This method has some advantages, for example, related
cellular and molecular biological techniques, and
techniques that are related to the ﬁgures and identiﬁcation

DETECTION METHODS OF CTCS
TABLE 1 | The strategies for isolation based on physical properties of CTCs.

CTCs are infrequent neoplastic cells, and a high-level detection
platform, appropriate equipment and techniques are needed to
detect its rather low concentration in blood, as approximately
one CTC per milliliter of blood can escape from primary
neoplasms or metastases. The properties to detect and separate
heterogeneous CTCs of all types, as well as to separate out the
large blood and white cells in blood, are necessary to for a CTC
testing platform. With results of negative or positive enrichment,
and recognizing circulating tumor cells or removing
hematopoietic cells through immune afﬁnity strategy, the
selection of CTCs is commonly the ﬁrst stage of detection. The
detection procedure then further distinguishes (and possibly

Frontiers in Oncology | www.frontiersin.org

Physical characteristics
Base on Density
Ficoll-Paque® (Density Medium Centrifugation)
Charge on Surface depFFF (Dielectrophoretic ﬁeld-ﬂow fractionation)
ApoStream®
Both Size and
Onco-Quick® (Porous barrier for size-based separation and
Density
density-based centrifugation)
Both Size and
Vortex chip
Deformability
Microﬂuid vortex capture
Size Only
DFF (Dean Flow Fractionation)
SSA (Selective size ampliﬁcation) in conjunction with MOA
(multi obstacle architecture)
ISET® (Isolation by Size of Epithelial tumor cells)
ScreenCell (Microporous membrane ﬁlter)
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of CTCs and their latent gene abnormalities, can
conveniently analyze neoplasm cells extracted onto the
ﬁlter. Furthermore, cells isolated from blood can undergo
tissue culture to be used in future experiments, without the
usage of any assay based on antibody, which can open up a
broad range of isolation areas for cancer cells, covering nonepithelial originated cells.
3. Electrical features (Surface charge):

identify CTCs in samples of liquid biopsy. Usually, two steps
are involved in these technologies, ﬁrstly CTC-enrichment,
followed by the step of enumeration and CTC detection.
Current positive selection detection procedures include the
CellSearch® system, Adnatest® system, MagSweeper™, CTC
Chips and Herringbone Chips, EPHESIA CTC Chips,
IsoFlux, Velcro-like devices, GEDI microdevices, and
DEPArray®.

The majority of cells of mammals have a net negativelycharged surface, especially in physiological situation. However,
because of the existence of some macromolecules that have
polarized particles, some cell surfaces have complex dielectric
features, such as proteins, nucleic acids and polypeptides.
For example, compared to leukocytes in blood, neoplasm cells
(e.g. CTCs) have a surface with more zeta potential or negative
charge, which has been demonstrated by studies. In addition,
these cells, compared to white blood cells, were also proven to
have lower cytoplasmic conductivity as well as higher unit
membrane capacitance (11).

For instance, the US FDA (Food and Drug Administration)
has approved the CellSearch® test system, which combines
immune-driven nano-magnetic beads with epithelial cell
adhesion molecules (EpCAM) through ﬂuorescent speciﬁc
CTC reaction recognition. It can be applied to breast
carcinoma and other malignancies treatment in addition to
patient monitoring after chemotherapy or surgeries. However,
independent validations of this novel technology are lacking.
2. Negative selection: Opposite to the former technology, based
on surface markers of cells that are quite different to nonCTCs, consumption procedures are used by negative selection
technology to remove white blood cells (WBCs) and other
blood cells. In negative CTC enrichment, WBCs are depleted
using antibodies of speciﬁcity against various biomarkers,
such as CD66b or CD45; this makes the selection of
leukocytes appearing in blood possible. However, not all
nucleated cells in blood are positive for CD66b or CD45.
Negative selection methods include white blood cells
depletion kits, CTC Chips, RosetteSep method, and Easysep
method.

Detection Methods Based on
Immunological Properties
This method identiﬁes CTCs by proteins on the cell surface or
DNA/RNA in cancer cells. Antibodies in blood can identify and
combine with speciﬁc markers, usually proteins, on cell surfaces.
For instance, epithelial markers are commonly used to identify
and separate blood cells and malignancy cells, due to features
commonly expressed on epithelial and epithelial cancer cells,
which are rarely expressed on the mesenchymal white
blood cells.
Immunology-based technology commonly uses speciﬁc
protein biomarkers, expressed by either cancer cells or blood
cells only, and their complementary antibodies. Circulating
tumor cells isolation tactics based on proteins can be
categorized into 3 types, as set out in Table 2.

For instance, the Easysep method is quick, simple, and does
not require a separation column of immune cells using magnetic
separation technology, along with other advantages. This method
depends on the TAC technology: normal cells are labeled with
antigen-antibody complex, under the action of immune
magnetic beads, and normal cells were placed in the EasySep™
magnetic pole, while CTCs were allowed to be negatively selected
and can thereafter be extracted from peripheral blood
mononuclear cells (PBMCs).

1. Positive selection: Speciﬁc markers usually expressed on the
surface of epithelial cancer cells or normal cells, such as
epithelial markers, are combined with antibodies, a design to

3. Selection-free CTCs can express EpCAM at varying levels (12).
Selection-free techniques for CTC recognition have been
developed, in that some cells express both mesenchymal
and epithelial phenotypes. This method combines high
throughput microscopy, ﬂow cytometry and RT-PCR. No
extra loss of CTCs during a selection procedure is one of the
advantages of these methods. Nevertheless, these methods
also have some restrictions, for example, CTCs and WBCs
need to be distinguished by imperfect biological markers.
Examples of selection-free methods include Epic Sciences and
AccuCyte® – CyteFinder®.

TABLE 2 | The strategies for isolation relied on biological features of CTCs.
Biological characteristics
Positive Selection

Negative Selection

Selection-free

Frontiers in Oncology | www.frontiersin.org

EPHESIA CTC-Chip
CellSearch® system
MagSweeper™
CTC-Chip and Herringbone-Chip
IsoFlux
Adnatest® system
Velcro-like device
GEDI microdevice
DEPArray®
leukocytes depletion kits
RosetteSep method
CTC-iChip
Epic Sciences
AccuCyte® – CyteFinder®

In Vivo Detection Methods
Optical Imaging Technology
Clinically, commonly used imaging technologies include MRI
(magnetic resonance imaging), PAT (Photoacoustic tomography),
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OCT (optical coherence tomography), CT (computed tomography)
and PET (positron emission tomography). Optical imaging
technologies, such as PAT and OCT, are much higher in velocity
and resolution than those of CT, MRI, and PET, and can even
identify circulating tumor cells in vivo. Optical imaging has been
proposed for real-time imaging of rapidly ﬂowing cells in blood
vessels, including cancer cells (13). Zerda et al., successfully detected
free RPMI-8226 myeloma cells in the blood vessels of rat ears by
means of speckle-modulating OCT (SM-OCT), which can
modulate speckle noise (13) and gold nanorods (~100 nm×
30 nm) were exploited as contrast agents to label cancer cells.
OCT technology was ﬁrst used for single cell detection in the
circulatory system within animals. The results show that optical
imaging techniques with high resolution can be taken to capture
ﬂuorescence-labeled cancer cells and non-labeled melanoma cells or
intravascular nanoparticles. However, precisely quantifying the
dynamic change of CTCs in fast ﬂowing blood is still very
difﬁcult because of the slow imaging velocity of these technologies.
In in vitro ﬂow cytometry (IVFC), as each cell passes through
the laser beam, ﬂuorescent markers on cell surfaces can be
suddenly activated to emit a ﬂuorescence. Quantiﬁcation of the
ﬂuorescent-labeled cells is done through data processing and
analysis. The natural blood circulation is directly exploited by
IVFC as the ﬂuid ﬂow system to quantitatively analyze the changes
of fast ﬂowing target cells in real-time. Different signals are
produced by target cells (CTCs) and other cells using different
methods such as contrast, ﬂuorescence, photothermal,
photoacoustic, light scattering intensity, etc. The methodology
for each type of ﬂow cytometry is based on those signals, such as in
vivo ﬂuorescence ﬂow cytometry, in vivo photoacoustic ﬂow
cytometry. Fluorescence IVFC (IVFFC) and photoacoustic IVFC
(IVPAFC) are the most widely used for CTC detection.

irradiates blood vessels with a high-frequency pulse laser and
detects the instantaneous ultrasonic signals generated by target
cells ﬂowing through the blood vessel through ultrasonic
detectors placed on the surface of tissue. The target cells
absorb light energy and then convert the light energy into heat
energy, when the tissue is irradiated. This causes the local
temperature to rise, which initiates a thermoelastic change in
the tissues, producing an ultrasonic wave (i.e., photoacoustic
signal). Compared to detection methods of CTCs in vitro,
IVPAFC has distinct merits. For instance, in the case of CTCs
metastases along lymphatic vessels, lymphatic system and vessels
should be enhanced and displayed by contrast agents because of
the small structure of lymphatic vessels, as well as the transparent
lymph liquid in the lymph vessels.
Besides, the collection amount of lymph ﬂuid is often too
small with long-term intubation, causing multiple restrictions in
the analysis of CTCs in lymph-based in vitro detection methods.
In CTC detection by IVPAFC, the background noise in
photoacoustic signals produced by colorless lymph is low,
which has signiﬁcant advantages. In the study, the researchers
used gold-plated carbon nanotubes and ligand-functionalized
iron trioxide magnetic nanoparticles to speciﬁcally mark breast
tumor cells MDA-MB-231 to evaluate detection levels of target
cells. Based on the same technique, others evaluated the
detection of CD44 expressing breast cancer stem cells. They
used IVPAFC to detect whether CTCs in breast cancer patients
have transferred to bone tissue and cerebrospinal ﬂuid, and
eventually proved that not only can IVPAFC detect melanoma
CTCs in vivo in real-time, it can also eradicate melanoma cells
and have signiﬁcant therapeutic effects.

Scaffold Implants
The implanted in vivo scaffold-based capturing technology
mainly stimulates the microenvironment in vivo, through
biomaterial scaffolds, to induce the migration of cancer cells
into the scaffolds. Shea et al. (15) implanted a Polylactide-coGlycolide (PLG) scaffold into mice and the results showed that
PLG scaffolds have the abilities to regulate the local immune
microenvironment, capture and recruit metastatic cancer cells,
and even decrease solid organs’ tumor burden. All the
biomaterials that used have great biocompatibility and can be
made into tissue engineering scaffolds or drug sustained-release
carriers, etc., which have broad biomedical applications.
Furthermore, other types of scaffolds could be used as targets
for SUM1315 breast tumor cells to metastasize in mice, such as
BMSCs (human bone stromal cells) and BMP-2 (bone
morphogenetic protein-2). For such patients, particularly those
with a high risk of recurrence, Scaffolds implantation can not
only help ﬁnd tumor metastasis at a relatively early stage, but also
treat breast cancer with a relatively low burden.

Fluorescence Flow Cytometry
A novel small animal research tool was developed by Tan et al.
called “Diffuse in vivo Flow Cytometry” (DiFC), which is used to
directly detect CTCs in blood, that are ﬂuorescently-labeled.
Near-infrared diffuse photons are used in this technique, making
it possible to count and identify cells ﬂowing in veins and large
superﬁcial arteries, and drawing of blood samples is not
necessary. The speed and depth can be measured and
individual cells of different directions in arterial or venous can
be counted when DiFC is combined with a new signal processing
algorithm. The experiment shows that all the blood of a mouse
can be easily monitored in under 10 minutes, while a false
positive rate of 0.014 per minute is maintained by DiFC, which
means DiFC is a credible tool to detect CTCs at concentration
levels even below 1 cell per milliliter. Therefore, DiFC is a
promising technology to be applied in biological applications.
In summary, IVFFC has been widely used to monitor the
dynamic changes of ﬂuorescently labeled CTCs in the blood
circulation system of animal tumor models, including single
CTCs, CTC clusters and apoptotic CTCs (14).

Intravenous Indwelling Needle Device
Intravenous indwelling needles (IINs) mainly consist of a
puncture needle core and an endovascular catheter. The
surface of the needle core tip is functionalized, allowing high
afﬁnity ligands such as antibody and aptamer to bind speciﬁcally
to CTCs. Another method is when the needle core is replaced

Photoacoustic Flow Cytometry

IVPAFC was ﬁrst developed by Zharov et al. of Arkansas
University. The mechanism of action is as follows: IVPAFC

Frontiers in Oncology | www.frontiersin.org
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given the dual sources of primary and metastatic tumors (19,20).
Because of that, increasingly more attention has been paid to
clinical applications of CTC detection in breast cancer.

with other biologically compatible materials, whereby CTCs can
be captured by inserting a catheter into blood vessels.
Presently, GILUPI CellCollector ® is the ﬁrst and only
technology approved by US FDA that captures CTCs through
IINs. The functionalized thread was laxly pushed into the elbow
venous vessel through the indwelling needle’s catheter (blood
ﬂow was about 20 mL per min) and stayed about 30 minutes in
order to capture CTCs. Thereafter, the thread was taken out,
washed, ﬁxed, sealed and immunostained it, and observed and
CTCs were counted under a microscope. CTCs are recognised
when cells show positive EpCAM or cytokeratin (CK) 4, 5, 8, 9,
18 and are between 10 and 50 micrometers in size and have a
high cytoplasmic ratio. The beneﬁt of this method is that it is
straightforward and quick, brings little trauma and is easily
accepted by patients with breast cancer.

Screening and Early Detection of Cancer
Early diagnosis plays a key role in decreasing mortality of breast
cancer, while various grades and types of breast cancer have
different signiﬁcance. For instance, the progress speed of grade I
is much more slow than grades II and III of breast cancer, which
means early diagnosis when the diameter of tumors is smaller
than two centimeters can improve prognosis and OR (overall
survival) of patients with breast cancer (21). CTC detection plays
a critical part in the screening, diagnosis, early detection and
treatment of breast cancer.
A quick CTCs detection method with great sensitivity has
been created by Kruspe et al. (22). CTCs‐derived nucleases, a
special enzyme that are usually elevated in multiple
malignancies, are used for signal ampliﬁcation in the study.
The result shows that probes activated by ﬂuorescent nucleases
are able to detect CTCs levels quickly, and can be an economical
and effective detection method of CTCs for early diagnosis of
breast cancer. Although CTC detection can detect breast cancer
earlier than conventional detection methods, further research on
CTC detection and its application in tumor diagnosis still needs
to be conducted, as using CTC for cancer diagnosis is still in the
preliminary phase of development.

Microﬂuidic Chip
Based on a sorting chip microﬂuidic cell, through an
arteriovenous shunt implanted in mice, the microﬂuidic chip
system has been tested when it is continuously connected to a
conscious mouse. When the blood passes through the
equipment, microﬂuidic valves which are pneumatically
controlled are able to capture CTCs, and the remaining blood
without CTCs will be go back into the mouse. An optoﬂuidic
system presented by Hamza (16) showed that the system
continuously collected CTCs labeled by ﬂuorescence from a
genetically engineered mouse model (GEMM) for several hours
per day over various days or weeks. Two-step microﬂuidic chips
were developed by Hyun (17), which can not only sort out
heterogeneous CTCs based on their features, but also isolate
CTCs from cells in blood. In conclusion, the microﬂuidic chips
are beneﬁcial to research on heterogeneity of CTCs, and by
extension, personalized tumor therapy. However, because of the
traumatic features of the insertion of catheter in veins and
arteries as well as the sterility requirement of CTCs sorting
devices and the materials’ biotoxicity, the application of
microﬂuidic chip is limited.

Predicting Recurrence and Prognosis in
Breast Cancer
It is commonly accepted that breast cancer malignant tumors
have a strong invasive ability that can migrate into remote
organs, such as bones and lungs, at an early stage. Therefore,
forecasting prognosis and cancer recurrence in breast cancer via
CTC detection plays a critical role in the treatment. There is a
plethora of studies which shows, as an independent predictor,
that the number of CTCs in blood before therapies have a
signiﬁcant implication in both OR (overall survival) and
progression-free survival of breast cancer patients (23).
The largest multicenter study was published by Rack and his
colleagues (24). In this study, they recruited 2,026 early breast
cancer patients in group 1 and 1,492 patients in group 2. Group 1
consists of patients before adjuvant chemotherapy, while group 2
consists of patients after chemotherapy, and both groups are
treated with the CellSearch System to count the number of CTCs.
According to the study, 21.5% of patients examined were
detected with CTCs in their blood, while CTCs can be found in
22.4% of node-positive patients and 19.6% of node-negative
patients. 22.1% of patients were detected with CTCs even after
chemotherapy. The continuous existence of CTCs in peripheral
blood is related to a worse prognosis, in the other words,
increased risk of recurrence in primary sites is related to an
elevated number of CTCs detected, before or after adjuvant
chemotherapy. Another similar study by Madic et al. (25)
probed the correlations of CTC and ctDNA plasma level with
the prognosis in patients with TNBC (triple negative breast
cancer). The study showed that worse prognosis and lower

CLINICAL APPLICATION OF CTCS IN
BREAST CANCER AND OTHER CANCERS
In 2020, breast cancer is on the top of malignancy lists in the world,
especially in developed areas. Identifying/diagnosing cancer and
metastatic tumors in an early stage is critically important for
clinicians to detect and treat breast cancer patients. Although the
prognosis is better than lung cancer and other malignancies, a
prominent characteristic of breast cancer is early metastasis, to
areas such as lungs, bones and brain, causing the elevated mortality
rates of breast cancer. As a prognostic tumor marker of treatment
efﬁcacy and metastatic progress with huge potential, CTCs count
has been proven and studied by multiple researchers (18).
Compared to conventional imaging diagnosis and tissue biopsy,
CTC is expected to be a non-invasive tumor screening method for
clinical application. In addition, compared to conventional tissue
biopsy, liquid biopsy captures the heterogeneous essence of tumors,
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overall survival and time of progression were related to those
patients with higher CTC counts. These studies point toward the
critical role of CTCs in forecasting relapse and prognosis in
patients with breast cancer.

Therefore, the tumor type can be identiﬁed through the
characteristics of circulating tumor cells. In addition to breast
cancer, CTC detection technology is also widely used in clinical
detection and clinical treatment of a variety of tumors, such as
prostate cancer, digestive tract cancer, small cell lung cancer, etc.
The CellSearch® system is the only US FDA-approved test
platform for CTC isolation, primarily for breast, prostate, and
colorectal cancer, and is considered the gold standard for CTC
testing. In metastatic prostate cancer, breast cancer, and
colorectal cancer, ≥5 circulating tumor cells per 7.5 mL of
blood are often associated with poor overall survival and
prognosis (23, 29, 30).
Prostate cancer is the most commonly occurring cancer,
besides breast cancer. Several large phase II and III trials have
established the prognostic value of CTCs in advanced prostate
cancer, especially metastatic castrated prostate cancer. The test
of CTC has gone beyond traditional PSA measurements to
prove to be the strongest independent predictor of survival and
has been approved by the FDA for monitoring prostate cancer
treatment (30, 31). However, in the hormone-sensitive stage
and early stage of prostate cancer, the clinical application of
CTC is still a huge challenge due to the very low level of CTCs.
In other words, the clinical application of CTC in prostate
cancer largely depends on the progression stage of the prostate
cancer itself.
Although the CellSearch® system has not been approved for
CTCs detection for lung cancer, a large number of clinical trials
have proved that CTCs detection has high clinical value in lung
cancer, and CTCs technology has been proven to be a predictor
of lung cancer prognosis. The number of CTCs in small cell lung
cancer is ten times that in non-small cell lung cancer, so
circulating tumor cells detection methods are mainly used in
small cell lung cancer (32–34). Real-time monitoring of CTCs in
the treatment of lung cancer enables prediction of disease
progression before clinical deterioration occurs. Similar to
breast cancer, a decrease in the number of CTCs in the blood
after surgery or chemoradiotherapy often indicates remission of
the disease. On the contrary, an increase in the number of CTCs
is often indicative of tumor metastasis and recurrence.
Interestingly, when He’s team detected CTCs in 165 patients
with benign pulmonary nodules, they found 5 CTC-positive
patients, and all of these patients developed lung cancer in the
next four years, suggesting that CTCs may have a unique role in
predicting the occurrence of lung cancer. T J N Hiltermann (35)
pointed out that the number of CTCs at baseline and the
dynamic change of CTCs after one month chemotherapy is an
independent predictor of small cell lung cancer. The number of
CTCs has no correlation with tumor response in small cell lung
cancer, so when forecasting the survival rate of the patients,
compared to the size and volume of tumor, spread of CTCs in
blood is more important. In addition, the role of CTCs in the
clinical prognosis of cancer has been widely recognized, and it is
used as an inﬂuencing factor to complement the traditional
TNM staging system, and is widely used in the diagnosis,
screening, long-term monitoring of lung cancer, as well as to
guide the treatment of lung cancer patients.

Recognition of Resistance Mechanisms
and Therapeutic Targets
ER/PR and HER-2 are therapeutic targets of breast cancer.
Clinical data show that in approximately 30% of cases, the
HER-2 status of distant metastatic tumor cells and CTCs are
signiﬁcantly different from that of cells in the primary site,
suggesting that drugs targeting the primary tumor may not be
appropriate for metastatic tumors. Detecting new properties and
characteristics of tumors through conventional tissue biopsy may
hurt patients; a non-invasive method like CTCs is an ideal
alternative. Other than ER/PR and HER-2, in recent years, the
discovery of immune checkpoint regulators such as PD-L1 has
made the successful therapy of advanced breast cancer possible,
which has become an exciting new therapeutic target. The
evidence that PD-L1 is expressed on the surface of CTCs in
breast cancer patients with ER or PR(+) and HER2(-) was ﬁrst
found by Mazel and his colleagues (26), and the established
assays of CTC/PD-L1 will be used for liquid biopsy in future
clinical experiments of breast cancer patients who are
experiencing the immune checkpoint.

Real-Time Monitoring of Therapies
After therapy such as surgery or chemotherapy, real time
detection of the level of CTCs in patients is needed to monitor
and evaluate their conditions and furthermore, predict and assess
survival period. During chemotherapy, the clinical validity of
CTCs quantiﬁcation via CellSearch method for monitoring was
assessed in metastatic breast cancer patients through analyzing
each patients’ real-time data of CTCs (27). Bidard et al. (28)
contacted 51 European centres and requested them to offer both
reported and unreported anonymized data for individual
metastatic breast cancer patients who took part in experiments
between January 2003 and July 2012. They concluded that when
added to full clinicopathological predictive models, CTCs count
can improve metastatic breast cancer’s prognostication, while
tumor markers in serum cannot, which means real time
monitoring of CTCs can not only detect and identify
deterioration, but also be used in the assessment and
monitoring of therapies.

The Clinical Application of CTCs of Other
Common Cancers
Through current techniques of CTCs detection, different cancer
types can be identiﬁed, this is usually done based on the physical,
chemical, and biological properties of the tumor cells. For
example, the source of the tumor can be determined by
detecting CTC phenotypes, immunohistochemistry, and
examining the genes of the cells. For example, KRT7 and TTF1 positive CTCs are associated with lung cancer, PSA and PSMA
positive cells are associated with prostate cancer, and KRT20 and
CDX2 positive cells are associated with colorectal cancer.
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amounts of CTCs have been detected in squamous cell
carcinoma of the head and neck, this largely depends on the
test method, the timing of blood collection, and the patient’s
clinical stage. Therefore, it is difﬁcult to apply CTC detection
techniques in the clinical treatment of head and neck tumors.
However, if CTCs could be captured under EMT, it would greatly
improve the detection of CTCs in head and neck tumors.
Therefore, large-scale clinical trials are necessary for head and
neck tumors, melanoma and other tumors with very low
numbers of CTCs.

In non-metastatic urinary carcinoma of the bladder, the
detection of CTCs was positively correlated with worse
progression-free survival, overall survival, tumor-speciﬁc
survival and relapse-free survival. In addition, in pure and
variant urinary carcinomas of the bladder, CTCs are an
independent prognostic factor (36). However, the presence of
CTCs in patients with seminogenic and non-seminogenic
testicular germ cell tumors is currently unknown (37).
Although EpCAM is often negative or very low in renal cell
carcinoma, one study claimed that it can detect CTC in 16% of
patients with metastatic renal cell carcinoma, and although the
detection level is low, it offers a glimmer of hope for the
application of CTCs in kidney cancer.
CTC detection technology is also widely used in digestive tract
tumors, and CTC count is signiﬁcantly correlated with the
metastasis and recurrence of digestive tract tumors, especially
colorectal cancer (36). Guus van Dalum et al. (38) conducted a
5-year follow-up of 183 colorectal cancer patients from Mayo
Hospital in the United States, and found that tumor patients
with a higher level of CTCs before surgery, had a shorter diseasefree survival and poorer prognosis after surgery. Surprisingly, the
appearance of CTCS a few weeks after surgery was not signiﬁcantly
correlated with RFS (recurrence-free survival) and CCRD, while
the appearance of CTCS two or three years after surgery was
signiﬁcantly correlated with RFS and CCRD. Preoperative CTCs in
stage I-III CRC patients were associated with signiﬁcantly reduced
RFS and CCRS. This suggests that the preoperative level of CTCs
can guide the chemotherapy of cancer patients. Similarly, in
esophageal and gastric cancers, higher preoperative CTCs were
associated with poorer postoperative outcomes (39). In pancreatic
cancer, the detection rate of CTCs in metastatic pancreatic cancer is
signiﬁcantly higher than that in non-metastatic pancreatic cancer,
and the level of CTCs has been shown to be one of the independent
inﬂuencing factors for overall survival after surgery. However, it is
difﬁcult to detect circulating tumor cells from pancreatic cancer in
peripheral blood, because CTCs are mostly blocked by the liver in
the portal vein. The presence of a large number of CTCs in the
portal vein is often indicative of liver metastasis. Therefore, a low
level of CTC in peripheral blood and a high level in the portal vein
is an important feature of the blood distribution in CTC analysis of
pancreatic cancer. A study of 88 patients with cholangiocarcinoma
(CCA) by Ju Dong Yang et al. (40) showed that CTCs were
detectable in patients with CCA and were an independent
predictor of survival in patients with CCA.However, given the
small sample size of the study and the absence of continuous blood
tests, it is not possible to determine whether CTCs predict overall
survival in patients with CCA.
Although CTC applications can be used in a wide range of
carcinoma, such as breast, prostate, rectal, small cell lung cancer
and pancreatic cancer, CTC detection is not suitable for all
tumors (41). According to some studies, the detection of CTCs
in a small number of gynecological tumors, neuroendocrine
tumors, head and neck tumors, and melanoma has not
achieved signiﬁcant results. This may be related to the mode of
metastasis of the tumor itself, the afﬁnity of antigens and
antibodies on the tumor surface, and the low number of CTCs
in the blood. For example, in recent years, although trace
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CONCLUSION AND DISCUSSION
Breast cancer is a malignant tumor usually known for its early
metastasis and high heterogeneity and cure rates. Early detection
and treatment can signiﬁcantly elevate survival rates in breast
cancer patients. CTCs have been proven to play a critically
important part in the diagnosis and therapy of breast cancer.
There are numerous CTC detection methods, which can be
generally divided into in vivo and in vitro methods, and can be
chosen on the basis of the requirements of the speciﬁc disease. At
present, in order to isolate CTCs with integrity, high vitality and
high purity, in vitro detection technology is able to capture and
release CTCs mildly, construct the negative selection method of
speciﬁc enrichment and remove normal blood cells to obtain
CTCs, and integrate the modules of in situ culture and analyze
the enriched CTCs immediately. There are two main methods
for quantitative analysis of CTCs in vivo. One is optic-based
IVFCs, which counts CTCs by optical signals. The other is to
capture CTCs, then stain tumor cells, and count the number of
cells under a microscope. Among them, the commercial
CellCollector is the most representative. The currently
developed in vivo capture technology of CTCs effectively
ensures the quality of CTCs before and during capture, but
downstream analysis of CTCs after in vivo capture is faced with
such problems as cell inactivation; new techniques need to be
developed to meet standards of CTC culture and molecular
analyses. In any case, the detection and molecular
characterization of CTCs remains challenging in that they are
exceedingly rare and the number of samples available is
extremely limited. Therefore, there is an urgent demand to
develop a novel system with higher sensitivity, convenience,
and efﬁciency. Clinically, compared with the conventional
“gold standard” of tissue biopsy, CTC detection and
monitoring can be acquired by routine blood sampling and is
an innovative technique using less invasive methods that can
sample consistently and repeatedly, so it is safer and timelier.
However, CTCs face many problems in terms of detection
technology, clinical application and biological challenges. At
present, there are many techniques and methods to detect CTCs
in blood, but all of them are faced with the issue of poor sensitivity,
which may lead to the delay of detection of tumor cell metastasis
in patients, thus delaying treatment. Compared with traditional
two-dimensional scaffolds, the implantation of three-dimensional
scaffolds and the increase of antibody loading can greatly improve
the sensitivity of CTC capture. In addition, although there are
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method that can collect each and every CTC in blood, and separate
the target cells and unspeciﬁc cells completely.
In general, the detection technology of CTCs is improving with
each passing day. It is hoped that the current difﬁculties will be
overcome in the near future, and CTC technology will be more
widely applied in clinical practice. As an emerging diagnosis and
treatment method, CTCs provides the possibility to ﬁnd and treat
breast cancer even at a stage before imaging methods can be used,
guide treatment in conjunction with other tumor markers,
monitor the treatment of patients after surgery, and predict the
prognosis of patients. In addition, there is growing evidence that
the current technology can be partially personalized for tumor
types, and CTCs can also be applied to other cancers, such as
prostate cancer, small cell lung cancer, straight colon cancer, etc.,
indicating that CTCs will signiﬁcantly advance the development of
precision oncology in the coming decades. However, CTCs still
face great clinical and biological challenges, such as low sensitivity,
small numbers, loss of cell activity and so on. Although it will be
challenging to improve the detection rate of CTCs, make full use of
CTCs for gene analysis of the primary tumor, and guide new
treatments according to the molecular targets on the surface of
CTCs, this also brings great hope for the further development of
biology and emerging immunotherapy techniques.

many different detection techniques, not one single technique can
detect all different types of circulating tumor cells.
Through the detection of CTCs, we not only expect to obtain
the dynamic change in the number of CTCs with the development
of the tumor, but also hope to obtain biological information related
to the phenotype, genome, transcriptome, proteome and
metabolome of the primary tumor from CTCs, which are of vital
importance in the ﬁeld of clinical treatment and biological research.
Current biological techniques only guarantee the activity of CTCs
before and during capture, but in vitro downstream analysis of
CTCs is faced with problems such as cell inactivation and
distortion, which greatly affects the application of CTCs in
clinical and biological engineering. Therefore, there is an urgent
need to develop a method to isolate CTCs in vitro with a mild and
speciﬁc technique for releasing captured CTCs, so that CTCs can
be completely released from the surface of detection system. There
is currently a lack of broad consensus on CDC isolation, extraction,
collection and preservation of samples, and selection of biomarkers.
In order to improve the accuracy of CTCs tests, a standard set of
performance assessment criteria should be developed, including
enrichment, cell viability and release efﬁciency, capture efﬁciency,
and purity. This will improve the sensitivity and speciﬁcity of CTC
detection and maximize the use of CTCs in the blood (which are
already scarce).
Although CTCs have great potential in real-time monitoring,
prognosis and diagnosis of tumors, CTCs alone cannot be used as
an effective indicator to guide the formulation of clinical treatment
plans for tumors. Large-scale clinical studies can be carried out in
combination with CTCs and other tumor markers, so as to
develop the index of circulating tumor cells combined with
tumor markers to guide the formulation of clinical tumor
programs, which will bring more far-reaching signiﬁcance and
improvements to the applications of circulating tumor cells in
clinical and bioengineering. For example, CTC testing in
combination with LDH measurements has been shown to be
superior to baseline serum LDH measurements alone, in the
evaluation of therapeutic efﬁcacy (31). In addition, the
biomolecular properties of CTCs have extremely important
properties, which can be used to evaluate tumor consistency,
prediction of site, speciﬁc metastasis, drug resistance map and
identiﬁcation of new drug targets, etc. Therefore, different subsets
of CTCs may lead to different clinical outcomes. This gives us an
important clue that the analysis of biomolecular properties of
individual circulating tumor cells can be used as a novel prognostic
or predictive marker to improve patient clinical outcomes. In
recent years, CTC research on single biological molecular
characteristics has made great progress, but due to the complex
detection technology of CTCs, there is still no single enrichment
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